Obese people are more likely to have diabetes, hypertension, joint issues, sleep problems- something we see around but choose to ignore everyday
Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes
Pregnancy and breastfeeding require avoiding both compounds entirely
Limit alcohol or other carbonated beverages that can irritate the stomach
Whether you need a powder-in-capsule or an enhanced formulation, Catalent can manufacture your clinical trial material under cGMP conditions to get you into clinic and beyond
GLP-1 medications are glucagon-like peptide-1 (GLP-1) receptor agonists approved for treating Type 2 diabetes and, more recently, for chronic weight management